The full Johnson & Johnson (JNJ) reaction history

JNJ news moved a median of +0.03% by the close. Every JNJ news event with the realized, point-in-time move the market made — the same measurement, headline by headline. Back to the JNJ overview →

Half of the 494 JNJ news events with a measured close landed between -0.56% and +0.54%; 51% closed up.

By year and event type

JNJ reaction counts across 4 years.

Event type2026202520242023Total
Press release12815212110411
SEC filing · Form 8-K81112435
SEC filing · Form 13F-HR644014
SEC filing · Form 10-Q33309
SEC filing · Form 11-K11204
SEC filing · Form DEFA14A11204
SEC filing · Form 10-K11103
SEC filing · Form ARS11103
SEC filing · Form DEF11103
SEC filing · Form N-PX11103
SEC filing · Form SD11103
SEC filing · Form 8-A12B01102
SEC filing · Form CERT01102
SEC filing · Form S-3ASR10001
All types15317915114497

Counts from the full measured window for JNJ, not just the free rows below — every event type we have labeled, year by year.

Archive pages

Older JNJ news pages.

Page 1 is the JNJ overview; pages 2–10 carry the rest of the measured list.

The 10 most recent JNJ reactions.

DateHeadlineEventSource5-minTo close
Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 StudyPress releasePR Newswire+0.11%-0.43%
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancerPress releasePR Newswire+0.07%+1.48%
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptidePress releasePR Newswire+0.07%+1.48%
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patientsPress releasePR Newswire+0.07%+1.48%
Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck CancerPress releasePR Newswire+0.98%+3.89%
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Shareholders to Inquire about Securities InvestigationPress releaseACCESS Newswire-0.05%-0.53%
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to ConnectPress releaseACCESS Newswire+0.06%+0.58%
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Johnson & Johnson (JNJ) And Encourages Shareholders to Reach OutPress releaseACCESS Newswire-0.63%-0.55%
Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study ResultsPress releaseBusiness Wire-0.63%-0.55%
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Shareholders to Learn More About the InvestigationPress releaseACCESS Newswire+0.08%-0.91%

487 more JNJ reactions are behind a free account. Create one to see all 497 measured JNJ events — the same point-in-time reactions, every headline.

See all 497 JNJ events →

No credit card · 100 free credits/mo

Keep exploring

More JNJ: earnings → · analyst actions → · SEC filings → · JNJ overview →

Other Health Care names, measured the same way

TickerEventsMedian 30-min% positive
Eli Lilly (LLY)2,000++0.03%52%
UnitedHealth Group (UNH)2,000+-0.03%48%

Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.